focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Mixed, IAG Drops Despite Guidance Upgraded

Fri, 30th Oct 2015 08:31

LONDON (Alliance News) - Stocks in London opened mixed Friday, with IAG as the worst blue-chip performer even though it reported a rise in operating profit in the third quarter and upgraded its profit guidance for 2015.

The FTSE 100 index opened down 0.1% at 6,389.83 points, the FTSE 250 was flat at 17,108.13, while the AIM All-Share was up 0.1% at 741.28. In Europe, the CAC 40 in Paris was up up 0.5% and the DAX 30 in Frankfurt was up 0.4%.

International Consolidated Airlines Group, which on Thursday approved its first dividend payment since it was created in 2011, said its operating profit in the third quarter to the end of September was EUR1.25 billion, up from EUR900.0 million a year earlier and still up to EUR1.21 billion when excluding the contribution from Aer Lingus Group, the Irish flag carrier IAG acquired this year.

For the nine months to the end of September, operating profit for the group was up to EUR1.77 billion from EUR1.05 billion a year earlier, a 69% rise.

The strong results in the quarter meant IAG has upgraded its operating profit guidance for the full year to EUR2.25 billion to EUR2.30 billion, a firmer target than the previous guidance for profit to be in excess of EUR2.20 billion. The new guidance also excludes any contribution from Aer Lingus.

Shares in the British Airways and Iberia owner were down 4.6% at the open.

Meanwhile, Royal Bank of Scotland Group was down 1.1%. It reported improved third-quarter net profit, as it booked a big gain on the loss of control of Citizens, the US retail bank it is selling, but warned that the costs of restructuring and addressing past conduct and litigation are not about to go away.

The bank said it made a GBP952 million net profit in the three months to September 30, compared with GBP896 million in the corresponding quarter the prior year. That included a GBP1.15 billion gain on the loss of control of Citizens, and the bank also confirmed that it is set to sell its remaining 20.9% stake in that bank.

Citizens Financial Group on Thursday said that RBS is now expected to exit its remaining 20.9% stake in the US retail bank. According to Citizens, RBS has launched a registered underwritten public offering to sell all of its remaining 110.5 million shares in the bank. RBS had previously set out plans to divest the rest of its stake by the end of 2015.

RBS peer Barclays was down 0.9% after several price target cuts from JPMorgan, Goldman Sachs, Exane BNP and Societe Generale. The bank closed Thursday as the biggest faller after it missed market expectations and cut guidance for 2016, as its adjusted pretax profit fell in the third quarter.

In the FTSE 250, Vectura Group is the best performer, up 4.7%, after it said it has secured two milestone payments following an approval of an inhaler in the US and after hitting a development milestone in Europe.

It said the US Food and Drug Administration has approved the dual combination Utibron Neohaler and Seebri Neohaler products for the long-term treatment of patients with chronic obstructive pulmonary disease. The approval has triggered a USD22.5 million milestone payment to Vectura from Swiss pharmaceuticals giant Novartis, Vectura's partner on the product.

Separately, the group has been paid a USD750,000 cash milestone after a further development milestone was hit for its VR632 therapy in the European Union. VR632 is an asthma and COPD inhaled treatment therapy which users Vectura's dry powder inhaler and formulation technology.

Outside company news, the Bank of Japan said that its Monetary Policy Board, governed by Haruhiko Kuroda, decided by an 8-1 majority vote to keep its target of raising the monetary base at an annual pace of about JPY80 trillion. The bank also maintained its asset purchase program unchanged.

Some economists had hoped that the Bank of Japan would announce additional stimulus, as the domestic economy is still struggling with deflation and a fits-and-starts recovery. The yen firmed up in reaction to the decision and is currently trading at the upper 120-range against the dollar.

"The market response suggests markets content with the status quo and especially the option for more QE later as well as the BoJ's confidence in a growth turnaround," said Accendo Markets analyst Michael van Dulken.

"Not dissimilar to the hawkish Fed statement mid-week seeing the positive outlook on growth outweighing the prospect of higher rates on the horizon. Markets still like cheap money, but may be coming round to a return to preference for actual growth," van Dulken added.

The Japanese Nikkei 225 index closed Friday up 0.8%. In China, the Shanghai Composite finished down 0.1%, while the Hang Seng in Hong Kong ended down 0.8%.

Wall Street ended mostly lower Thursday, with the DJIA down 0.1%, the S&P 500 flat and the Nasdaq Composite down 0.4%.

Growth in US economic activity slowed in the third quarter, according to a report released by the Commerce Department on Thursday. The report said annualised real gross domestic product rose by 1.5% in the third quarter compared to the 3.9% jump seen in the second quarter. Economists had expected a 1.7% increase.

In the economic calendar Friday, eurozone inflation and unemployment are at 1000 GMT. In the US, personal consumption data is at 1230 GMT, the Chicago purchasing managers' index is at 1345 GMT, and the Reuters/Michigan consumer sentiment index is at 1400 GMT.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
26 Nov 2018 09:05

Vectura Discontinues VR375 As Phase Three Study Misses Endpoints

LONDON (Alliance News) - Respiratory disease-focused pharmaceutical firm Vectura Group PLC said on Monday its phase three study of VR375 in adult and adolescent patients with severe uncontrolled a

Read more
22 Oct 2018 08:59

Vectura Says New Chief Financial Officer Fry Has Started Week Early

LONDON (Alliance News) - Medical devices developer Vectura Group PLC said Monday Paul Fry will become chief financial officer immediately, rather than from Monday next week.Fry succeeds who

Read more
11 Sep 2018 09:40

Vectura Interim Loss Narrows On Higher Revenue And Lower Expenses

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC on Tuesday said its loss narrowed in the first half of 2018 as it reduced operating costs.Pretax loss narrowed to GBP29.9 in a

Read more
11 Sep 2018 08:18

Vectura's solid interims turn focus further forward

(Sharecast News) - Vectura kept guidance for the full year unchanged as the inhaled medicines specialist reported robust revenue and said it has identified pipeline projects with potential annual sales of over $250m.

Read more
10 Sep 2018 12:49

Vectura Launches Flutiform Inhaler In The UK, Europe To Follow

LONDON (Alliance News) - Vectura Group PLC said Monday that it launched its flutiform k-haler, an inhaler to treat asthma, in the UK.The company said it expects further launches across to a

Read more
4 Sep 2018 15:54

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 5 SeptemberĀ Barratt DevelopmentsFull Year ResultsBreedon GroupHalf Year Year 6

Read more
23 Aug 2018 14:17

Thursday broker round-up

(Sharecast News) - TalkTalk: Barclays upgrades to overweight with a target price of 150p.

Read more
21 Aug 2018 12:31

Vectura concludes two paediatric studies into VR647

(Sharecast News) - Vectura announced the successful conclusion of two paediatric studies to support the potential use of VR647, its wholly-owned drug/device combination asset, on Tuesday.

Read more
21 Aug 2018 09:45

Vectura Group Gets Positive Results From VR647 Phase II Study

LONDON (Alliance News) - Vectura Group PLC said Tuesday that it received positive results form two paediatric studies of its VR647 inhalation system to manage asthma.The two studies, a and

Read more
17 May 2018 10:55

Vectura Group On Track To Achieve Expected Full-Year Revenue

LONDON (Alliance News) - Inhaled product design and development firm Vectura Group PLC said on Thursday based on its trading performance for the year-to-date revenue is currently in line with is a

Read more
11 May 2018 11:35

Nuformix Appoints Former Ventura Chief Executive To Board

LONDON (Alliance News) - Pharmaceutical company Nuformix PLC said Friday that it has appointed Christopher Blackwell, the former chief executive officer of Vectura Group PLC, as non-executive of a

Read more
10 May 2018 16:16

UK Shareholder Meetings Calendar - Next 7 Days

Friday 11 MayBBA AviationMan GroupRSA Insurance GroupJohn Wood Advanced 14 15 Pacific

Read more
24 Apr 2018 13:16

Sosei Group Confirms It Will Not Make Takeover Offer For Vectura

LONDON (Alliance News) - Japanese biotechnology firm Sosei Group Corp said on Tuesday, noting unspecified press reports, it does not intend to make an offer for Vectura Group PLC.Shares in

Read more
23 Apr 2018 09:55

Vectura Adds Ex-GSK And Sanofi Executive Whitaker To Board From June

LONDON (Alliance News) - Vectura PLC said Monday it has appointed Anne Whitaker as non-executive director of the drug development firm from the start of June.Whitaker served as president of

Read more
20 Apr 2018 09:59

Vectura CFO Andrew Derodra Leaves To Take Up Role At Unilabs

LONDON (Alliance News) - Vectura Group PLC on Friday said that its Chief Financial Officer Andrew Derodra will leave the FTSE 250-listed respiratory medicines maker to take a new role within the a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.